CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Omeprazole +1 moredrug
Likely dose
Omeprazole 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00557349
NCT00557349Phase 4Completed
CompareCT.gov

A Randomized, Double-blind Clinical Trial Comparing Zegerid Capsule to Famotidine in Preventing Anastomotic (Marginal) Ulcers in Post Gastric Bypass Patients

University of Missouri-Columbia·interventional·Posted Nov 14, 2007·Updated Jan 19, 2017

In Brief

A Phase 4 clinical trial evaluating Omeprazole and Famotidine for Marginal Ulcers. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This research is to determine which medication, Zegerid (Omeprazole/Sodium Bicarbonate) or Pepcid AC (Famotidine), works best at reducing the chance that a patient will get an ulcer after gastric bypass surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarginal Ulcers
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 14, 2007
Enrollment StartNov 1, 2006
Primary CompletionNov 1, 2007
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.6 years ago

Interventions

Omeprazoledrug

40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.

Famotidinedrug

40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.